Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Peter Lwabi, Bongani Mayosi, Chinthanie Ramasundarahettige, Sumathy Rangarajan, Kumar Balasubramanian, Divya Pattath, Amy Krol, Martin van Eikels, Alexander Benz, Wadea M Tarhuni, Tantchou T J Cabral, Sanjib K Sharma, Pilly Chillo, Salim Yusuf, Onkabetse J Molefe-Baikai, Okechukwu S Ogah, Maria Paniagua, Changsheng Ma, Lillian Gondwe, Liesl Zühlke, Khawar Kazmi, John Musuku, J Antonio Gonzalez-Hermosillo, Golden Fana, Fathi Maklady, Emmanuel R Kamanzi, Dayi Hu, Bernard Gitura, Antonio M L Dans, Alvaro Avezum, Albertino Damasceno, Alaa El Ghamrawy, Ahmed El Sayed, Abraham Haileamlak, Mpiko Ntsekhe, Ganesan Karthikeyan, Stuart J Connolly
The New England journal of medicine 2022;387(11):978-988